Ruxience Prices, Coupons, Copay Cards & Patient Assistance
Ruxience (rituximab) is a member of the CD20 monoclonal antibodies drug class and is commonly used for Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and others.
The cost for Ruxience (pvvr 10 mg/mL) intravenous solution is around $764 for a supply of 10 milliliters, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Ruxience prices
Intravenous Solution
pvvr 10 mg/mL
Ruxience intravenous solution
from $764.29
for 10 milliliters
Quantity | Per unit | Price |
---|---|---|
10 milliliters | $76.43 | $764.29 |
50 milliliters | $75.67 | $3,783.45 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Ruxience Coupons, Copay Cards and Rebates
Ruxience offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
Drugs.com Printable Discount Card
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Print Free Discount CardNote: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, CVS Pharmacy, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.
Ruxience Pfizer Oncology Together Co-Pay Savings Program for Injectables
Eligible commercially insured patients may pay as little as $0 per treatment subject to a maximum savings of $25,000 per calendar year.
- Applies to:
- Ruxience
- Number of uses:
- per prescription per calendar year
- Expires
- December 31, 2024
Form more information phone: 877-744-5675 or Visit website
Ruxience enCompass Co-Pay Assistance Program Copay Claim (Rebate)
Eligible commercially insured patients may submit a Copay Claim Form if they paid in full for treatment while enrolled and couldn't use Program benefits; for patients with Rheumatoid Arthritis.
- Applies to:
- Ruxience
- Number of uses:
- One rebate per prescription fill
Form more information phone: 844-722-6672 or Visit website
Ruxience (for Rheumatoid Arthritis Patients) enCompass Co-Pay Assistance Program
Eligible commercially insured patients may pay $0 co-pay per prescription with savings of up to $20,000 per calendar year.
- Applies to:
- Ruxience
- Number of uses:
- Per prescription per calendar year
Form more information phone: 844-722-6672 or Visit website
Ruxience Pfizer Oncology Together Copay Claim (Rebate)
Eligible commercially insured patients may submit a Copay Claim Form if they paid their provider or pharmacy in full for treatment while enrolled in the Program and were unable to use the Program benefits; for additional information contact the program at 877-744-5675.
- Applies to:
- Ruxience
- Number of uses:
- One rebate per prescription fill
- Expires
- December 31, 2024
Form more information phone: 877-744-5675 or Visit website
Ruxience Medicare Part D Extra Help Subsidy
Patients with Medicare Part D coverage may be eligible for the Extra Help Subsidy, which may lower premiums and prescription costs. Contact the program for more information.
- Applies to:
- Ruxience
- Number of uses:
- Per prescription until program expires
Form more information phone: 800-772-1213 or Visit website
Patient Assistance & Copay Programs for Ruxience
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: HealthWell Foundation Copay Program
Eligibility requirements:- May have insurance
- Varies
- FDA Approved Diagnosis - See Program Website for Details
- The patient must also be residing in the US.
- This program provides financial assistance to eligible individuals to cover coinsurance, copayments, healthcare premiums and deductibles for certain treatments. Also, for those who are eligible for health insurance, but cannot afford the insurance premium, the foundation may be able to help by paying some or all of the medical portion of insurance premiums. The patient is being treated for a specific disease for which funding is available and has insurance that covers the treatment for this disease. Call for most recent medications as the list is subject to change.
- Ruxience (rituximab-pvvr) Injection; IV
More information please phone: 800-675-8416 Visit Website
Provider: Patient Access Network Foundation (PAN)
Eligibility requirements:- *See Additional Information section below
- Between 400-500% of FPL
- FDA Approved Diagnosis - See Program Website for Details
- Must reside and receive treatment in US
- *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance.Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
- Ruxience (rituximab-pvvr) Injection; IV
More information please phone: 866-316-7263 Visit Website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
More about Ruxience (rituximab)
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: CD20 monoclonal antibodies
- Breastfeeding
- En español
Patient resources
- Ruxience drug information
- Ruxience (Rituximab Intravenous) (Advanced Reading)
- Ruxience (Rituximab-pvvr Intravenous) (Advanced Reading)